Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura
Latest Information Update: 13 May 2019
At a glance
- Drugs Sumatriptan (Primary) ; Sumatriptan
- Indications Migraine with aura; Migraine without aura
- Focus Registrational; Therapeutic Use
- Acronyms COMPASS
- Sponsors Avanir Pharmaceuticals; OptiNose
- 07 May 2019 Results applying novel analytic approach for measuring consistency of response in the acute treatment of episodic migraine using data from the COMPASS study published in the Headache
- 16 Oct 2017 Results published in the Headache
- 10 Sep 2017 Results (n=259) comparing efficacy and tolerability of sumatriptan tablets versus sumatriptan delivered intranasally in adult patients with acute migraine with or without aura, were presented at the 2017 International Headache Society.